KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024Business Wire • 02/21/24
KORU Medical Systems to Participate in Piper Sandler's 35th Annual Healthcare ConferenceBusiness Wire • 11/29/23
KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion SystemBusiness Wire • 11/08/23
KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 OutlookBusiness Wire • 11/08/23
KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled SyringesBusiness Wire • 11/07/23
KORU Medical Systems to Report Third Quarter Financial Results on November 8, 2023Business Wire • 10/25/23
KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National ConferenceBusiness Wire • 10/05/23
KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of DirectorsBusiness Wire • 10/04/23
KORU Medical Systems to Participate in the Gilmartin Group Emerging Growth Company ShowcaseBusiness Wire • 09/15/23
KORU Medical Systems, Inc. Announces 2023 Second Quarter Financial Results and Updates Full Year 2023 OutlookBusiness Wire • 08/09/23
KORU Medical Systems to Participate in the Genuity 43rd Annual Growth ConferenceBusiness Wire • 08/08/23
KORU Medical Systems, Inc. Announces Preliminary Second Quarter 2023 Revenues and Provides Business, Outlook and Executive UpdatesBusiness Wire • 08/02/23
KORU Medical Systems to Report Second Quarter Financial Results on August 9, 2023Business Wire • 07/31/23
KORU Medical Systems Announces Novel Therapies Collaboration for Late-Stage Endocrinological BiologicBusiness Wire • 07/27/23
KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60® Infusion System With Hizentra® 50 Ml Prefilled SyringesBusiness Wire • 07/10/23
KORU Medical Systems to Report First Quarter Financial Results on May 4, 2023Business Wire • 04/21/23